Ann: Skin scarring webinar featuring Professor Fiona Wood, page-24

shall we interpret it the new drug is a re-do of previous 6302 Phase 1? although via an improved version?
The company is still letting Prof Wood to "investigate" 6302 but potentially abandoned the burn scar and change the focus on less Commercially attractive Keloid, fund and supported by Syntara. it's officially off the on-going pipeline of company.
I believe they had a good and reasonable explanation, however still feel like a setback --- again this is just what I see it, maybe wrong.